Furthermore, several combination approaches with ICIs, such as Nivolumab combined with Ipilimumab (anti-cytotoxic T-lymphocyte-associated protein-4 (CTLA-4)) and Atezolizumab (anti-PD-L1) combined with Bevacizumab, have been approved to improve therapeutic efficacy in HCC patients [47,48]. The gene discussed is CTLA4; the disease is hepatocellular carcinoma.